O.C.G.A. § 31-52-3 (2019)

As used in this chapter, the term:

(1) ‘‘Eligible patient’’ means a person who meets the requirements of Code Section 31-52-4.

(2) ‘‘Investigational drug, biological product, or device’’ means a drug, biological product, or device which has successfully completed Phase I of a federal Food and Drug Administration approved clinical trial but has not yet been approved for general use by the federal Food and Drug Administration and currently remains under investigation in a federal Food and Drug Administration approved clinical trial.

(3) ‘‘Physician’’ means a person licensed to practice medicine pursuant to Article 2 of Chapter 34 of Title 43.

(4) ‘‘Terminal illness’’ means a disease that, without life-sustaining procedures, will result in death in the near future and is not considered by a treating physician to be reversible even with administration of current federal Food and Drug Administration approved and available treatments.

(5) ‘‘Written informed consent’’ means a written document that:

(A) Is signed by the patient; parent, if the patient is a minor; legal guardian; or health care agent designated by the patient in an advance directive for health care executed pursuant to Chapter 32 of Title 31;

(B) Is attested to by the patient’s physician and a witness; and

(C) Meets the requirements of Code Section 31-52-5.